Natera company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

natera.com

Founded Year

2004

Stage

PIPE | IPO

Total Raised

$151.6M

Market Cap

3.29B

Stock Price

34.20

Revenue

$0000 

About Natera

Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to help families diagnose and manage genetic disease.

Natera Headquarter Location

201 Industrial Road Suite 410

San Carlos, California, 94070,

United States

650-249-9090

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Natera

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Natera in 1 CB Insights research brief, most recently on Jan 20, 2021.

Expert Collections containing Natera

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Natera is included in 6 Expert Collections, including Cancer.

C

Cancer

3,710 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

M

Medical Devices

8,110 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

2,470 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

O

Omics

1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

12,795 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health IT

7,900 items

Natera Patents

Natera has filed 151 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Genetics
  • DNA
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/14/2021

5/10/2022

Molecular biology, Genetics, DNA, Biotechnology, DNA sequencing

Grant

Application Date

5/14/2021

Grant Date

5/10/2022

Title

Related Topics

Molecular biology, Genetics, DNA, Biotechnology, DNA sequencing

Status

Grant

Latest Natera News

Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Natera, Inc.

May 15, 2022

. Radnor, Pennsylvania--(Newsfile Corp. - May 14, 2022) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that the firm has filed a securities class action lawsuit against Natera, Inc. ("Natera") (NASDAQ: NTRA) on behalf of all persons and entities who purchased or otherwise acquired Natera common stock between February 26, 2020, and April 19, 2022, inclusive (the "Class Period"). PLEASE CLICK HERE TO VIEW OUR COMPLAINT, PLEASE CLICK HERE LEAD PLAINTIFF DEADLINE: JUNE 27, 2022 CLASS PERIOD: FEBRUARY 26, 2020 through APRIL 19, 2022 CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS: James Maro, Esq. (484) 270-1453 or Email at info@ktmc.com Kessler Topaz is one of the world's foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent. NATERA'S ALLEGED MISCONDUCT Natera, a Delaware corporation with principal executive offices in Austin, Texas, offers genetic testing in the areas of women's health, oncology, and organ health. Among other things, the Company produces and markets a non-invasive prenatal test (NIPT), called "Panorama," and a screening test for kidney transplant failure, called "Prospera." Throughout the Class Period, Defendants repeatedly assured investors that Panorama was reliable, that Prospera was more accurate than competing tests, and that Natera's growth was driven by its superior technology and customer experience. Investors, however, began to learn the truth on January 1, 2022, when The New York Times published a detailed report calling into question the accuracy of certain prenatal tests manufactured by Natera and other diagnostic testing companies. Among other things, The New York Times reported that Natera's positive results for several genetic disorders were incorrect more than 80 percent of the time. On this news, the price of Natera common stock fell $5.35 per share, or approximately 6% over two trading days, from a close of $93.39 per share on December 31, 2021, to close at $88.04 per share on January 4, 2022. Less than two weeks later, on January 14, 2022, the Campaign for Accountability-a nonprofit watchdog group-filed a complaint with the U.S. Securities and Exchange Commission requesting an investigation as to whether Natera repeatedly claimed - in marketing materials and earnings calls - that its tests are much more reliable than it appears they really are. On this news, the price of Natera common stock fell $6.29 per share, or more than 9%, from a close of $67.37 per share on January 14, 2022, to close at $61.08 per share on January 18, 2022. Then, on March 9, 2022, Hindenburg Research issued an investigative report alleging, among other things, that "Natera's revenue growth has been fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers." On this news, the price of Natera common stock fell as much as $28.65 per share, or more than 52%, from a close of $54.75 per share on March 8, 2022, to an intra-day low of $26.10 per share on March 9, 2022. Several days later, on March 14, 2022, a jury found that Natera had intentionally and willfully misled the public by utilizing false advertisements to market Prospera in violation of federal and state laws. Among other things, the jury found that Natera's marketing falsely claimed that Prospera was more accurate than the competing kidney transplant testing offered by CareDx, Inc. Ultimately, the jury awarded CareDx, Inc. $44.9 million in monetary damages. On this news, Natera common stock fell as much as $8.81 per share, or approximately 22.5%, from an intra-day high of $39.13 per share on March 14, 2022, to close at $30.32 per share on March 15, 2022. Finally, on April 19, 2022, the United States Food and Drug Administration (FDA) issued a safety communication "to educate patients and health care providers and to help reduce the inappropriate use of [NIPTs]." The FDA cautioned that statements about NIPTs' reliability and accuracy "may not be supported with sound scientific evidence" and revealed the existence of "cases where a screening test reported a genetic abnormality and a confirmatory diagnostic test later found that the fetus was healthy." The FDA suggested that patients discuss benefits and risks with a healthcare provider before deciding to undergo NIPT or making any pregnancy-related decisions on the basis of NIPT results. In addition, the FDA advised health care providers that they should not rely on NIPT results alone to diagnose chromosomal abnormalities or disorders. Following this news, the price of Natera common stock fell as much as $1.53 per share, or approximately 3.9%, from an intra-day high of $39.63 per share on April 19, 2022, to close at $38.10 per share on April 20, 2022. The complaint alleges that, throughout the Class Period, the Defendants misrepresented and/or failed to disclose that: (1) Panorama was not reliable and resulted in high rates of false positives; (2) Prospera did not have superior precision compared to competing tests; (3) as a result of Defendants' false and misleading claims about Natera's technology, the company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, Defendants' statements about the company's business, operations, and prospects lacked a reasonable basis. WHAT CAN I DO? Natera investors may, no later than June 27, 2022, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP encourages Natera investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE WHO CAN BE A LEAD PLAINTIFF? A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com . CONTACT: James Maro, Jr., Esq. Radnor, PA 19087

Natera Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Natera Rank

You May Also Like

J
JJET

JJET is committed to the development, production, and sales of products in the field of electrophysiology, the products mainly include a three-dimensional cardiac mapping system, multi-channel physiological recorder, cardiac electrophysiological stimulator, cardiac radiofrequency ablation device, cold saline perfusion pump, cardiac electrophysiological mapping catheter, cardiac radiofrequency ablation catheter, nerve radiofrequency treatment instrument.

R
Rubicor Medical

Rubicor Medical is a private medical device company located in Redwood City, California. Our proprietary biopsy technology (Ovation Breast Biopsy Device) is a dramatic improvement over current minimally invasive biopsy technologies. The Ovation system is comprised of a 14-gauge biopsy device capable of excising, capturing and extracting an intact 2.5 cm diameter tissue sample. Ovation is compatible with either ultrasound or stereotactic image guidance. Rubicor was co-founded by Dr. James Vetter and has been privately funded by a consortium of individual investors.James W. Vetter, M.D., CEO and Chairman of the Board, is a board certified interventional cardiologist.He is an Associate Professor of Clinical Medicine at Stanford University Hospital, where he iscurrently on Active Staff status as community faculty. Dr. Vetter is a graduate of the MedicalCollege of Wisconsin where he completed a residency in internal medicine and a fellowship incardiology. Dr. Vetter completed an interventional cardiology fellowship with Dr. John SimpsonM.D./PhD., at Sequoia Hospital, Redwood City, California. Dr. Vetter is a member of the Alpha OmegaAlpha Honor Society and the American College of Cardiologists. He has published six articles andseveral book chapters as well as over 35 abstracts. Dr. Vetter has held positions as a member of thePhysician Advisory Council and/or board member with a number of medical device companiesincluding Guidant, Lumend, Fox Hollow and CardioVasc. He is also a board member of MagellanSystems International, Inc.Dr. Vetter has extensive experience in working with new medical device concepts and designs,working with R&D engineers to develop working prototypes and clinically testing and refining thoseproducts. He was co-founder of Perclose and was involved with that company from inception toinitial public offering and eventual sale to Abbott Labs. He is a "hands on" clinician with access toresources and expertise needed to build a successful medical device and company. Dr. Vetter hashad a number of patents issued in his name as co-inventor.Ary Chernomorsky, V.P. of R&D since 2000 has over 23 years experience in the medical deviceindustry. Prior to joining Rubicor, Mr. Chernomorsky was employed by the Vascular Therapiesdivision of US Surgical Company (acquired by Tyco International), where he served as a Director ofR&D. Mr. Chernomorsky has been involved with various startup companies in the R&D Director andManager capacities including: PAS Inc. (acquired by USS), Advanced Surgical, Inc. (acquired byImagyn), Micro Therapeutics, Bausch and Lomb, Mentor Corporation and Dart Industries Inc. Aryholds an M.S. in Polymer Engineering from LIT and an M.S. in Biomedical Engineering from RutgersUniversity.Tony Difede, CPA, V.P. Finance holds a BSBA degree in Accounting from the University of Floridaand a M.S. in Taxation from Pace University. He has held management positions in tax and accountingwith Ernst & Young, KPMG and my CFO, Inc. His clients have included closely held start-upcompanies as well as large multinational public corporations. He is licensed in California and NewJersey. He has extensive experience in accounting for stock options and issues regarding closelyheld companies and their high net worth owners and investors.COMPANY INFOMANAGEMENTpage 12006 Company Overview (Continued)Breast care. Completely redefined.James W. Vetter, M.D., Founder and Chairman of the Board, is a board certified interventionalcardiologist. He is an Associate Professor of Clinical Medicine at Stanford University Hospital,where he is currently on Active Staff status as community faculty. Dr. Vetter is a graduate of theMedical College of Wisconsin where he completed a residency in internal medicine and a fellowshipin cardiology. Dr. Vetter completed an interventional cardiology fellowship with Dr. JohnSimpson M.D./PhD., at Sequoia Hospital, Redwood City, Cal

C
Columbia BioSystems

Columbia BioSystems Inc. is a company engaged in molecular Nano-diagnostics using Molecularly Imprinted Polymers (MIPs) for the rapid detection of pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA) , Anthrax, HIV, and Trypanosomiasis (sleeping sickness). The company uses MIPs to bind to proteins and, upon binding, change color thereby signaling the presence of the bacteria, virus or parasite.

X
Xeptagen S.p.A.

XEPTAGEN SpA is engaged in the discovery and validation of molecular markers in order to produce diagnostic kits for the early detection, monitoring, and screening of cancerous cells. By exploiting the natural immune response to early stage cancer and the platform technology Combinatorial Proteomic, XEPTAGEN has discovered specific tumor markers that lead to an earlier and much more accurate detection of developing carcinomas. The company's mission includes creating tools that improve the diagnostic accuracy for cancer and the clinical management of cancer patients.

F
Flex Biomedical

Flex Biomedical is developing technologies to treat and diagnose orthopedic diseases. Flex Biomedical's lead product is a synthetic polymer, the Flex Polymer, designed to treat osteoarthritis.

M
MicroPhage

MicroPhage's mission is to be a worldwide pioneer in rapid bacterial diagnostics, in both bacterial identification and antibiotic susceptibility/resistance testing, through its bacteriophage-based amplification platform for immunoassay diagnostics.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.